Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

@inproceedings{Tokalov2009ProtectionOP,
  title={Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment},
  author={Sergey V. Tokalov and N. D. Abolmaali},
  booktitle={BMC Cancer},
  year={2009}
}
Mutations within the tumor suppressor TP53 gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy. The lack of the wild type TP53 gene in cancer cells could be exploited for therapeutic advantage using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu and H1299) by taxol and to protect p53 wild type cells (A549) by the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Antiangiogenic activity of the MDM2 antagonist nutlin-3.

Circulation research • 2007
View 4 Excerpts
Highly Influenced

MDM2 inhibitors for cancer therapy.

Trends in molecular medicine • 2007
View 3 Excerpts
Highly Influenced

Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…